Cardiovascular disease: risk assessment and reduction, including lipid modification
KEYWORDS: people, cvd, risk, treatment, statin, statins, committee, recommendations, prevention, evidence, cholesterol, recommendation, lipid-lowering, primary, amended

and dose of statin. [2014, amended December 2023] 1.9.4 Advise the person that any statin at any dose reduces CVD risk. [2014, amended May 2023 and December 2023] For a short explanation of why the committee made the 2023 recommendation and how it might affect practice, see the rationale and impact section on optimising statin treatment. Full details of the evidence and the committee's discussion are in evidence review C: statins: efficacy and adverse effects. 1.10 Treatment if statins are contraindicated or not tolerated Also see the section on assessing response to treatment. Primary prevention of cardiovascular disease 1.10.1 Ezetimibe is recommended as an option in NICE technology appraisal guidance for treating primary hypercholesterolaemia in adults if statins are contraindicated or not tolerated. For full details, see the guidance on ezetimibe (TA385, 2016). 1.10.2 Bempedoic acid with ezetimibe is recommended as an option in NICE technology appraisal guidance for treating primary hypercholesterolaemia or mixed dyslipidaemia if statins are contraindicated or not tolerated, and ezetimibe alone does not control LDL cholesterol well enough. For full details, see the guidance on bempedoic acid with ezetimibe (TA694, 2021). Secondary prevention of cardiovascular disease 1.10.3 Offer ezetimibe instead of a statin to people for
